Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Contributed by: Business Wire

Logo

Tags

Health

Consumer

Women

Other Health

Pharmaceutical

Biotechnology

Dermavant

More Like This

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Innovaderm, a Key Collaborator in Clinical and Study Development for Recently Published Phase 1 Atopic Dermatitis Study

Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults

Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress

PR Newswire associated0

Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada

Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting

Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024

PR Newswire associated0

Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics